Withdrawals due to adverse events not measured · patients with extensor carpi radialis tendinitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
Paracetamol showed no clear difference in withdrawals due to adverse events 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.54, 2.18]
Studies not reported
Very low
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 1.41 [0.81, 2.47]
Studies not reported
Low
Withdrawals due to adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with osteoarthritis
Chondroitin showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with axSpA (AS and nr‐axSpA)
COX‐2 NSAIDs showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 2.14 [0.36, 12.56]
669 participants
Low
Withdrawals due to adverse events · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in withdrawals due to Adverse events compared with placebo + MTX/DMARD (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review
Withdrawals due to adverse events · Patients with ankylosing spondylitis
Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review